Latest news with #PetMedExpress
Associated Press
03-07-2025
- Business
- Associated Press
PetMed Express Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K
DELRAY BEACH, Fla., July 03, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. ('PetMeds®') (NASDAQ: PETS) received on July 2, 2025, an expected notice (the 'Notice') from The Nasdaq Stock Market LLC ('Nasdaq') indicating that, as a result of not having timely filed its Annual Report on Form 10-K for the fiscal year ended March 31, 2025 (the 'Form 10-K'), with the Securities and Exchange Commission ('SEC'), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the 'Listing Rule'), which requires timely filing of all required periodic financial reports with the SEC. The Notice has no immediate effect on the listing or trading of the Company's common stock on Nasdaq. The Notice indicated that the Company must submit a plan to regain compliance with the Listing Rule within 60 calendar days, or until September 1, 2025, and following receipt of such plan, Nasdaq may grant an exception of up to 180 calendar days from the Form 10-K due date, or until December 29, 2025, for the Company to regain compliance. On June 16, 2025, the Company filed a Notification of Late Filing on Form 12b-25 indicating that it was unable, without unreasonable effort or expense, to file its Form 10-K by the prescribed due date because the Company is continuing to compile, review, and analyze the information necessary to complete its financial statements and related disclosures to be included in the Form 10-K, as more fully described in the Company's Current Report on Form 8-K filed with the SEC on July 1, 2025. While the Company can provide no assurances as to timing, the Company is working diligently to complete its financial statements for its fiscal year ending March 31, 2025, and the Form 10-K and plans to file the Form 10-K as soon as practicable to regain compliance with the Listing Rule. About PetMed Express, Inc. Founded in 1996, PetMeds is a pioneer in the direct-to-consumer pet healthcare sector. As a trusted national online pharmacy, PetMeds is licensed across all 50 states and staffed with expert pharmacists dedicated to supporting pet wellness and the veterinarians who serve them. Through its PETS family of brands, the Company offers a comprehensive range of pet health solutions - including top-brand and generic pharmaceuticals, compounded medications, and better-for-your-pet OTC supplements and nutrition. Focused on value, convenience, and care, PetMeds and PetCareRx empower pet parents to help their dogs, cats, and horses live longer, healthier lives. To learn more, visit and Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. Words such as 'may,' 'could,' 'expect,' 'project,' 'outlook,' 'strategy,' 'intend,' 'plan,' 'seek,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'potential,' 'strive,' 'goal,' 'continue,' 'likely,' 'will,' 'would' and other similar words and expressions are intended to signify forward-looking statements. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by the Company and its management, are inherently uncertain and are subject to various risks and uncertainties, including: statements regarding the Company's ability to complete the filing of the Form 10-K within the anticipated time period; the Company's ability to regain compliance with Nasdaq listing standards; and the time required to complete the Company's financial statements for its fiscal year ending March 31, 2025. The Company's future results may also be impacted by other risk factors listed from time to time in the Company's filings with the SEC, including, but not limited to, the Company's Annual Report on Form 10-K for the year ended March 31, 2024, as well as other subsequent filings on Form 10-Q and periodic filings on Form 8-K. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing the Company's views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements, other than as may be required by law. If the Company does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements. Investor Contact: ICR, LLC John Mills Reed Anderson (646) 277-1260 [email protected]
Yahoo
10-06-2025
- Business
- Yahoo
PetMed Express, Inc. Announces Delay in Fourth Quarter and Fiscal Year End Earnings Release and Conference Call
DELRAY BEACH, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced it is delaying the release of the Company's fourth quarter and fiscal year 2025 earnings release and subsequent conference call, which had been scheduled for June 10, 2025, because the Company requires additional time to complete the year-end audit process. The Company anticipates that it will issue the earnings release, hold the related conference call, and file its Annual Report on Form 10-K as soon as possible, but no later than June 16, 2025. About PetMed Express, Inc. Founded in 1996, PetMeds is a leader in pioneering the digital pet pharmacy industry. As a national online retailer, and are top choices for delivering preventive and chronic symptom prescriptions and OTC medications and products through their thousands of veterinary partners and a loyal customer base. Leveraging telehealth and insurance partnerships, they offer value and convenience to pet families at every stage of their pets' lives, whether dogs, cats, or horses. PetMeds and PetCareRx provide a comprehensive range of medications, food products, and essential supplies through their websites, and Investor Contact: ICR, LLCJohn Mills(646) 277-1254Reed Anderson(646) 277-1260investor@ in to access your portfolio
Associated Press
07-05-2025
- Business
- Associated Press
PetMed Express, Inc. and Dutch Announce Partnership to Provide Accessible Telehealth Services for Pets
DELRAY BEACH, Fla. and OAKLAND, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc., parent company of PetMeds and PetCareRx (Nasdaq: PETS), today announced a new strategic partnership with virtual veterinary care provider Dutch . The collaboration marks PetMeds' latest move to expand its provider ecosystem with affordable, accessible pet healthcare options. The new partnership will enable pet parents to leverage Dutch's convenient technology and veterinary team to secure prescriptions for PetMeds' broad selection of medications in a timely manner. 'This partnership expands the accessibility of pet telemedicine, which can help fill gaps in care, as the nationwide vet shortage has left more than 129 million Americans without easy access to pet care,' said Joe Spector, Founder and CEO of Dutch. 'Through this collaboration, we are looking forward to reaching a broader audience of pet parents in need of care and medications.' 'At PetMeds, we believe the veterinarian is—and will always be—at the center of a pet's healthcare journey,' said Sandra Campos, President and CEO of PetMeds. 'By integrating Dutch's virtual care platform into our growing pet health ecosystem, we're expanding access to timely, professional care, particularly when in-person visits aren't possible due to geography, timing or cost. This partnership is designed to support the 200 veterinarians who are employed by Dutch and aid continuity of care while helping ensure pet parents receive expert guidance, whenever and wherever it's needed.' Under the partnership, pet parents will be able to sign up for a monthly Dutch membership and be connected virtually with veterinarians for 24/7 appointments in 34 states. Since launched, Dutch has completed almost 700,000 visits and offers treatment options for over 150 conditions, including flea and tick medication and treatments for allergies and joint pain. Consumer awareness and adoption of veterinary telehealth options are accelerating as pet parents look for more affordable, accessible ways to keep their beloved pets healthy and happy. Dutch's recently released 2025 State of Veterinary Care Report found that 129 million Americans, or roughly 38% of the population, live in vet-care 'deserts'—underscoring the significant need for more accessible pet care options. About PetMed Express, Inc. Founded in 1996, PetMeds is a leader in the consumer pet healthcare sector. As a national online retailer with expert pharmacists and licenses across fifty states, and deliver top branded pharmaceuticals, generics, compounded prescription medications and OTC supplements and vitamins that help pets live longer, healthier lives. The Company strives to offer unparalleled value and convenience that enhance wellness and longevity for dogs, cats, and horses. PetMeds and PetCareRx provide essential pet health offerings through their websites, and . About Dutch Launched in July 2021, Dutch is the first and only veterinary telehealth company connecting licensed, independent veterinarians directly with pets and their parents nationwide. At its inception, Dutch primarily addressed common chronic ailments, such as anxiety and allergies, but has grown to treat over 150 conditions and serve over 40,000 customers. In 2022, Dutch introduced Rx services, which allow the company's licensed veterinarians to prescribe and ship OTC and prescription medications to patients in 34 states. Dutch memberships, excluding insurance, begin at just $15/month, and include unlimited access to virtual veterinary care through video and chat models. In a country experiencing a critical vet shortage of just one veterinarian for every 6,000 pet households, Dutch is creating a more accessible means of dependable, quality vet care that can address the modern pet parents' needs in a timely manner and at a fraction of the cost. Media Contacts For PetMeds: Danielle Poggi [email protected] Reed Anderson [email protected] For Dutch: Melissa Stavenhagen [email protected]
Yahoo
06-02-2025
- Business
- Yahoo
The past five years for PetMed Express (NASDAQ:PETS) investors has not been profitable
PetMed Express, Inc. (NASDAQ:PETS) shareholders should be happy to see the share price up 14% in the last month. But will that repair the damage for the weary investors who have owned this stock as it declined over half a decade? Probably not. Indeed, the share price is down a whopping 81% in that time. While the recent increase might be a green shoot, we're certainly hesitant to rejoice. The million dollar question is whether the company can justify a long term recovery. We really feel for shareholders in this scenario. It's a good reminder of the importance of diversification, and it's worth keeping in mind there's more to life than money, anyway. Now let's have a look at the company's fundamentals, and see if the long term shareholder return has matched the performance of the underlying business. Check out our latest analysis for PetMed Express Given that PetMed Express didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size. In the last five years PetMed Express saw its revenue shrink by 2.2% per year. While far from catastrophic that is not good. The share price fall of 13% (per year, over five years) is a stern reminder that money-losing companies are expected to grow revenue. We're generally averse to companies with declining revenues, but we're not alone in that. Fear of becoming a 'bagholder' may be keeping people away from this stock. You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values). It's probably worth noting we've seen significant insider buying in the last quarter, which we consider a positive. On the other hand, we think the revenue and earnings trends are much more meaningful measures of the business. So we recommend checking out this free report showing consensus forecasts We'd be remiss not to mention the difference between PetMed Express' total shareholder return (TSR) and its share price return. The TSR attempts to capture the value of dividends (as if they were reinvested) as well as any spin-offs or discounted capital raisings offered to shareholders. Its history of dividend payouts mean that PetMed Express' TSR, which was a 77% drop over the last 5 years, was not as bad as the share price return. PetMed Express shareholders are down 9.6% for the year, but the market itself is up 24%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. However, the loss over the last year isn't as bad as the 12% per annum loss investors have suffered over the last half decade. We'd need to see some sustained improvements in the key metrics before we could muster much enthusiasm. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For instance, we've identified 2 warning signs for PetMed Express (1 is a bit concerning) that you should be aware of. If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: most of them are flying under the radar). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
